The Europe anticoagulants market is estimated to grow with a CAGR of 8.48%, during the forecast years of 2021 to 2028. The region’s market growth is primarily attributed to factors such as the increased prevalence of atrial fibrillation and venous thromboembolism (VTE), the rising healthcare expenditure, the surging obese and geriatric population, and the growing adoption of NOACs.

EUROPE ANTICOAGULANTS MARKET FORECAST 2021-2028

Europe Anticoagulants Market by Application (Atrial Fibrillation & Heart Attack, Pulmonary Embolism (Pe), Deep Vein Thrombosis (Dvt), Stroke, Other Applications) by Route of Administration (Oral Anticoagulants, Injectable Anticoagulants) by Drug Class (Noacs (Xarelto, Eliquis, Pradaxa, Savaysa & Lixiana, Bevyxxa), Heparins & Low-molecular-weight Heparins (Lmwhs), Vitamin K Antagonists, Other Drug Class) and by Geography.

Request free sample

Report Summary

The Europe anticoagulants market is estimated to grow with a CAGR of 8.48%, during the forecast years of 2021 to 2028. The region’s market growth is primarily attributed to factors such as the increased prevalence of atrial fibrillation and venous thromboembolism (VTE), the rising healthcare expenditure, the surging obese and geriatric population, and the growing adoption of NOACs.
europe-anticoagulants-market

To learn more about this report, request a free sample copy

The Europe anticoagulants market growth is assessed by evaluating the United Kingdom, Poland, France, Russia, Germany, Italy, Belgium, and the rest of Europe. The United Kingdom harbors a well-established healthcare system, owing to which the country’s anticoagulants market observes a growing trend. Moreover, the rising geriatric population and the increasing incidence of cardiovascular conditions play an essential role in driving the country’s market growth. For instance, according to the report by the Centre for Ageing Better, in 2019, more than 11.9 people, aged 65 and over, lived in the United Kingdom. However, this figure is anticipated to increase by more than 40%, within the next two decades.

As per the Fondation de France, one in every three people in France, carry significant risk factors, in terms of cardiovascular diseases (CVDs). Likewise, according to a published study, CVDs are the primary cause of death in the country, despite neurodegenerative diseases and cancer posing larger threats to the population. As a result, these factors are anticipated to drive the Europe anticoagulants market growth, over the forecast period.

Leo Pharma AS, headquartered in Denmark, is a pharmaceutical enterprise that engages in the research and development, production, and commercialization of dermatological products. It offers medicines for patients suffering from skin conditions, such as plaque psoriasis and diseases that need intensive care and supportive treatments.

 

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    Table of Contents

    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      •    KEY DRIVERS
        • SURGING PREVALENCE OF CHRONIC DISEASE
        • ADVANCEMENTS IN TECHNOLOGY
        • RISING APPROVAL OF NOVEL ORAL ANTICOAGULANTS (NOACS)
      •    KEY RESTRAINTS
        • SIDE EFFECTS ASSOCIATED WITH ANTICOAGULANTS TREATMENT
        • HIGH PRICE OF NOACS
        • STRINGENT GOVERNMENT REGULATIONS
    1. KEY ANALYTICS
      •    PORTER’S FIVE FORCES ANALYSIS
        • THREAT OF NEW ENTRY
        • THREAT OF SUBSTITUTION
        • BUYER’S POWER
        • SUPPLIER’S POWER
        • COMPETITIVE RIVALRY
      • IMPACT OF COVID-19 ON ANTICOAGULANTS MARKET
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • KEY INVESTMENT INSIGHTS
    2. MARKET BY APPLICATION
      • ATRIAL FIBRILLATION & HEART ATTACK
      • PULMONARY EMBOLISM (PE)
      • DEEP VEIN THROMBOSIS (DVT)
      • STROKE
      • OTHER APPLICATIONS
    3. MARKET BY ROUTE OF ADMINISTRATION
      • ORAL ANTICOAGULANTS
      • INJECTABLE ANTICOAGULANTS
    4. MARKET BY DRUG CLASS
      • NOACS
      • HEPARINS & LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS)
      • VITAMIN K ANTAGONISTS
      • OTHER DRUG CLASS
    5. GEOGRAPHICAL ANALYSIS
      •    EUROPE
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        •   COUNTRY ANALYSIS
          • GERMANY
          • FRANCE
          • UNITED KINGDOM
          • ITALY
          • RUSSIA
          • BELGIUM
          • POLAND
          • REST OF EUROPE
    1. COMPETITIVE LANDSCAPE
      •    KEY STRATEGIC DEVELOPMENTS
        • MERGER & ACQUISITIONS
        • PRODUCT LAUNCH & DEVELOPMENTS
        • PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
        • BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
      •    COMPANY PROFILE
        • ABBOTT LABORATORIES
        • ALEXION PHARMACEUTICAL INC
        • ASPEN PHARMACARE HOLDINGS LIMITED
        • BAYER AG
        • BOEHRINGER INGELHEIM GMBH
        • BRISTOL-MYERS SQUIBB COMPANY
        • DAIICHI SANKYO
        • REDDY’S LABORATORIES
        • GLAXOSMITHKLINE PLC
        • JOHNSON & JOHNSON
        • LEO PHARMA AS
        • MERCK & CO.
        • NOVARTIS AG
        • PFIZER INC
        • SANOFI

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – ANTICOAGULANTS

    TABLE 2: EUROPE ANTICOAGULANTS MARKET, BY APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 3: EUROPE ANTICOAGULANTS MARKET, BY APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 4: EUROPE ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 5: EUROPE ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 6: EUROPE ANTICOAGULANTS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 7: EUROPE ANTICOAGULANTS MARKET, BY DRUG CLASS, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 8: EUROPE ANTICOAGULANTS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

    TABLE 9: EUROPE ANTICOAGULANTS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

    TABLE 10: LEADING PLAYERS OPERATING IN EUROPE ANTICOAGULANTS MARKET

    LIST OF FIGURES

    FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

    FIGURE 2: OPPORTUNITY MATRIX

    FIGURE 3: VENDOR LANDSCAPE

    FIGURE 4: KEY INVESTMENT INSIGHTS

    FIGURE 5: EUROPE ANTICOAGULANTS MARKET, BY APPLICATION, IN 2020

    FIGURE 6: EUROPE ANTICOAGULANTS MARKET, BY ATRIAL FIBRILLATION & HEART ATTACK, 2021-2028 (IN $ MILLION)

    FIGURE 7: EUROPE ANTICOAGULANTS MARKET, BY PULMONARY EMBOLISM (PE), 2021-2028 (IN $ MILLION)

    FIGURE 8: EUROPE ANTICOAGULANTS MARKET, BY DEEP VEIN THROMBOSIS (DVT), 2021-2028 (IN $ MILLION)

    FIGURE 9: EUROPE ANTICOAGULANTS MARKET, BY STROKE, 2021-2028 (IN $ MILLION)

    FIGURE 10: EUROPE ANTICOAGULANTS MARKET, BY OTHER APPLICATIONS, 2021-2028 (IN $ MILLION)

    FIGURE 11: EUROPE ANTICOAGULANTS MARKET, BY ROUTE OF ADMINISTRATION, IN 2020

    FIGURE 12: EUROPE ANTICOAGULANTS MARKET, BY ORAL ANTICOAGULANTS, 2021-2028 (IN $ MILLION)

    FIGURE 13: EUROPE ANTICOAGULANTS MARKET, BY INJECTABLE ANTICOAGULANTS, 2021-2028 (IN $ MILLION)

    FIGURE 14: EUROPE ANTICOAGULANTS MARKET, BY DRUG CLASS, IN 2020

    FIGURE 15: EUROPE ANTICOAGULANTS MARKET, BY NOACS, 2021-2028 (IN $ MILLION)

    FIGURE 16: EUROPE ANTICOAGULANTS MARKET, BY HEPARINS & LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS), 2021-2028 (IN $ MILLION)

    FIGURE 17: EUROPE ANTICOAGULANTS MARKET, BY VITAMIN K ANTAGONISTS, 2021-2028 (IN $ MILLION)

    FIGURE 18: EUROPE ANTICOAGULANTS MARKET, BY OTHER DRUG CLASS, 2021-2028 (IN $ MILLION)

    FIGURE 19: EUROPE ANTICOAGULANTS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

    FIGURE 20: GERMANY ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

    FIGURE 21: FRANCE ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

    FIGURE 22: UNITED KINGDOM ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

    FIGURE 23: ITALY ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

    FIGURE 24: RUSSIA ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

    FIGURE 25: BELGIUM ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

    FIGURE 26: POLAND ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

    FIGURE 27: REST OF EUROPE ANTICOAGULANTS MARKET, 2021-2028 (IN $ MILLION)

    Segmentation

    1. GEOGRAPHICAL ANALYSIS
      •    EUROPE
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        •    COUNTRY ANALYSIS
          • GERMANY
          • FRANCE
          • UNITED KINGDOM
          • ITALY
          • RUSSIA
          • BELGIUM
          • POLAND
          • REST OF EUROPE
    1. MARKET BY APPLICATION
      • ATRIAL FIBRILLATION & HEART ATTACK
      • PULMONARY EMBOLISM (PE)
      • DEEP VEIN THROMBOSIS (DVT)
      • STROKE
      • OTHER APPLICATIONS
    2. MARKET BY ROUTE OF ADMINISTRATION
      • ORAL ANTICOAGULANTS
      • INJECTABLE ANTICOAGULANTS
    3. MARKET BY DRUG CLASS
      • NOACS
      • HEPARINS & LOW-MOLECULAR-WEIGHT HEPARINS (LMWHS)
      • VITAMIN K ANTAGONISTS
      • OTHER DRUG CLASS

    Request Free Sample

    To request a free sample copy of this report, please complete the form below :
    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type

      Get In Touch

      Inquire Before Buying

      Customization

      Inkwood Research delivers customized reports as per the client's requirement to provide them with an edge in the competitive market

      Request Customization

      RELATED REPORTS